Abstract
Agonist-replacement therapies have been successfully used for treatment of opiate and nicotine addiction, but not for cocaine addiction. One of the major obstacles is the cocaine-like addictive potential of the agonists themselves. We report here an atypical dopamine (DA) transporter (DAT) inhibitor, CTDP-32476, that may have translational potential for treating cocaine addiction. In vitro ligand-binding assays suggest that CTDP-32476 is a potent and selective DAT inhibitor and a competitive inhibitor of cocaine binding to the DAT. Systemic administration of CTDP-32476 alone produced a slow-onset, long-lasting increase in extracellular nucleus accumbens DA, locomotion, and brain-stimulation reward. Drug-naive rats did not self-Administer CTDP-32476. In a substitution test, cocaine self-Administration rats displayed a progressive reduction in CTDP-32476 self-Administration with an extinction pattern of drug-Taking behavior, suggesting significantly lower addictive potential than cocaine. Pretreatment with CTDP-32476 inhibited cocaine self-Administration, cocaine-Associated cue-induced relapse to drug seeking, and cocaine-enhanced extracellular DA in the nucleus accumbens. These findings suggest that CTDP-32476 is a unique DAT inhibitor that not only could satisfy 'drug hunger' through its slow-onset long-lasting DAT inhibitor action, but also render subsequent administration of cocaine ineffectual-thus constituting a novel and unique compound with translational potential as an agonist therapy for treatment of cocaine addiction.
Original language | English (US) |
---|---|
Pages (from-to) | 682-694 |
Number of pages | 13 |
Journal | Neuropsychopharmacology |
Volume | 42 |
Issue number | 3 |
DOIs | |
State | Published - Feb 1 2017 |
Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology
- Psychiatry and Mental health